Evidence map›Paper›PMID 41398426›Full record

ArticleScientific reports2025

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.

Manoj Garg, Deepika Kanojia, Anand Mayakonda, Trivadi S Ganesan, Bindhya Sadhanandhan, Sidhanth Suresh, Sneha S, Rohit P Nagare, Jonathan W Said, Ngan B Doan and 5 more

Abstract readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Manoj GargCancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore. manoj.garg@cancerinstitutewia.org.
Deepika KanojiaCancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore.
Anand MayakondaCancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore.
Trivadi S GanesanDepartment of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar, Chennai, India.
Bindhya SadhanandhanDepartment of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar, Chennai, India.
Sidhanth SureshDepartment of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar, Chennai, India.
Sneha SDepartment of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar, Chennai, India.
Rohit P NagareDepartment of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar, Chennai, India.
Jonathan W SaidDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA.
Ngan B DoanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA.
Ling-Wen DingCancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0003-0022-1551
Erkan BalogluKaryopharm Therapeutics Inc, Newton, MA, 02459, USA.
Sharon ShachamKaryopharm Therapeutics Inc, Newton, MA, 02459, USA.
Michael KauffmanKaryopharm Therapeutics Inc, Newton, MA, 02459, USA.
H Phillip KoefflerCancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0001-5839-9913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41398426
PMCPMC12705672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.